The effect of simvastatin on dyslipemia in continuous ambulatory peritoneal dialysis patients.
The efficacy of simvastatin, an inhibitor of HMG-CoA reductase, was evaluated in 14 nondiabetic hypercholesterolemic continuous ambulatory peritoneal dialysis (CAPD) patients with or without hypertriglyceridemia. Following a hypolipemic diet for 6 weeks, simvastatin was administered at a dose of 10 mg/day for 6 months. After 6 weeks on simvastatin, cholesterol was reduced by 22% (p < 0.001), triglycerides by 24% (p < 0.001), low-density lipoprotein (LDL) by 27% (p < 0.001), while high-density lipoprotein (HDL) increased by 18% (p < 0.005). These changes remained steady for 6 months. Apolipoprotein-B (Apo-B) was reduced by 17.8% (p < 0.0001), while Apo-A was stable. There were no liver function abnormalities observed. In 3 patients serum creatinine kinase (CK) was increased, and in 2 treatment was stopped. No new lens opacities or other side effects were detected. Simvastatin seems to be an effective and relatively well-tolerated drug for dyslipemias in CAPD.
CAPD Unit, 1st Department of Internal Medicine, Aghios Dimitrios Hospital, Thessaloniki, Greece.
A
A
Dimitriadis
S
S
Antoniou
N
N
Hatzisavvas
F
F
Pastore
I
I
Kaldi
M
M
Stangou
D000328:Adult; D000368:Aged; D001053:Apolipoproteins / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood; D008148:Lovastatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D019821:Simvastatin
D001053:Apolipoproteins; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D002784:Cholesterol; D008148:Lovastatin; D019821:Simvastatin